EURUSD Bid: --
USDJPY Bid: --
GBPUSD Bid: --
USDCHF Bid: --
AUDUSD Bid: --
USDCAD Bid: --
NZDUSD Bid: --
EURGBP Bid: --
GBPJPY Bid: --
WTI Bid: --
BRENT Bid: --
XAUUSD Bid: --
XAGUSD Bid: --
SPX500 Bid: --
DAX40 Bid: --
US30 Bid: --
JPN225 Bid: --
NAS100 Bid: --
UK100 Bid: --
BTCUSD Bid: --
ETHUSD Bid: --
LTCUSD Bid: --
XRPUSD Bid: --
EURUSD Bid: --
USDJPY Bid: --
GBPUSD Bid: --
USDCHF Bid: --
AUDUSD Bid: --
USDCAD Bid: --
NZDUSD Bid: --
EURGBP Bid: --
GBPJPY Bid: --
WTI Bid: --
BRENT Bid: --
XAUUSD Bid: --
XAGUSD Bid: --
SPX500 Bid: --
DAX40 Bid: --
US30 Bid: --
JPN225 Bid: --
NAS100 Bid: --
UK100 Bid: --
BTCUSD Bid: --
ETHUSD Bid: --
LTCUSD Bid: --
XRPUSD Bid: --

iFOREX Prices London IPO at £43.3M After Eight-Month Delay

Posted: 19th Feb 2026

iFOREX Financial Trading Holdings Ltd. has priced its initial public offering (IPO) on the London Stock Exchange at 195 pence per share, setting the company's market capitalization at roughly £43.3 million. Trading under the ticker IFRX is expected to begin on February 25.

The IPO caps a drawn-out path to the public markets. iFOREX had originally planned to list in late June 2025 before pulling the plug on those plans, citing a routine compliance inspection in the British Virgin Islands that needed more time to complete. The company only confirmed the process had restarted two days ago, describing it as being at an "advanced stage."

iForex Placing Draws Oversubscribed Demand

The offering consists entirely of 4,487,179 new ordinary shares, with no existing shareholders selling down their stakes. At 195p, the raise totals £8.75 million, around 20.2 percent of the company's share capital following admission. The placing was oversubscribed, according to the company, suggesting demand from institutional investors exceeded the available allocation.

Getting here has been anything but straightforward, and the broader IPO environment for financial firms has not made things easier. Just last week, prime broker Clear Street pulled its own listing after a 40% valuation cut, spooked by software sector selloffs and crypto market volatility.

Shore Capital and Corporate Limited is acting as sponsor, while Shore Capital Stockbrokers Limited is serving as sole bookrunner for the listing. Both are regulated by the Financial Conduct Authority.

Founder Keeps a Firm Grip

Eyal Carmon, iFOREX's founder, is not selling shares in this offering and will remain the majority shareholder after listing. He has entered into a relationship agreement that takes effect on admission and will continue advising the business through a consultancy arrangement with Recap Ltd., a company he wholly owns. The directors, proposed directors, and certain senior employees holding shares through an employee ownership trust have agreed to a 12-month lock-up, followed by a subsequent 12-month orderly market period.

"Today marks a pivotal moment in iFOREX's evolution as we prepare to list on the Main Market of the London Stock Exchange," CEO Itai Sadeh framed the listing as a platform for growth. "The oversubscribed placing reflects investor confidence in our strategy, solid fundamentals and scalable operating model."

If the listing goes ahead as planned, iFOREX would join a short list of publicly traded online brokers, a list that has barely changed since 2016, despite years of speculation about which firm might go next.

Since then, only eToro has joined the list, last year, but FX and CFD brokers have historically avoided public markets, citing regulatory complexity, earnings volatility, and the difficulty of explaining their business models to generalist investors. iFOREX is betting that a London listing changes that calculus, at least for itself.

Profit Fell Sharply Even as Revenue Held Steady

The IPO arrives at a time when iFOREX's financials have been under pressure. An earlier FinanceMagnates.com analysis showed the broker lost around 20% of its clients and saw profits drop by 75% over two years ahead of the original listing attempt. For the year ended December 31, 2024, the company reported trading income of $50.1 million and adjusted pre-tax profits of $7.6 million, while net profit fell 31% to just above $5 million.

The full prospectus, published today, includes new data. The first half of 2025 showed revenue recovering, $27.6 million versus $22.6 million in H1 2024, helped in part by Trump's crypto endorsements in February 2025 and the tariff-driven market volatility in April.

But operating profit collapsed to just $420,000 in H1 2025, compared to $4.6 million in the same period a year earlier, as selling and marketing costs ballooned to $21.3 million - up 36% year-on-year.

The prospectus is candid about what happened in the third quarter of 2025. Revenue fell to roughly $7.7 million with an adjusted EBITDA loss of approximately $3.1 million. The company attributes the miss to three factors: unusually low global market volatility, disruption caused by the IPO delay (which meant increased prior marketing spend didn't translate into the brand benefit of being listed), and a short-term revenue initiative the company itself describes as "ineffective" and which was "promptly reversed."

The business recovered in Q4 2025, generating approximately $13.5 million in revenue and $2 million in adjusted EBITDA. For the full year 2025, the company expects revenue of around $49 million, broadly flat with 2024.

LSE Main Market

Listing on the Main Market, rather than the smaller AIM segment, subjects iFOREX to the full weight of FCA oversight and UK premium listing standards, which could help with institutional credibility but also increase disclosure obligations and compliance costs. The company is also in the process of obtaining a UK financial services license.

The prospectus, now approved by the FCA, is available on the National Storage Mechanism and the company's investor relations page. Potential investors are advised to rely solely on that document, including its risk factors, before making any investment decision. The company notes that the offering is directed only at qualified investors in the UK and EEA, and is not available to investors in the United States, Canada, Australia, South Africa, or Japan.

This article was written by Damian Chmiel at www.financemagnates.com.

Source: Finance Magnates

Follow us on
Website Managed by BuiltByGo
Disclaimer: The information provided on FX Axe is for educational and informational purposes only and should not be construed as financial advice. Trading Foreign Exchange (FX), Contracts for Difference (CFDs), and other leveraged financial products involves a high level of risk and may not be suitable for all investors. Leverage can work both to your advantage and disadvantage, and as a result, you may lose more than your initial investment. Before deciding to trade FX, CFDs, or any other financial instrument, you should carefully consider your investment objectives, level of experience, and risk tolerance. You should not invest money that you cannot afford to lose. It is strongly advised that you seek independent financial advice if you have any doubts. FX Axe does not provide investment, tax, legal, or financial advice of any kind. We may receive compensation from brokers and partners featured on this website, but such relationships do not influence our reviews or recommendations. All reviews are based on our own opinions and research and should not be interpreted as endorsements or guarantees of any service. Past performance is not indicative of future results. The trading of FX and CFDs carries a significant risk of loss. By using this website, you acknowledge that FX Axe bears no responsibility for any losses you may incur from your trading activities or reliance on information provided here.

Affiliate Disclosure: Some of the links and references on FX Axe may relate to third-party brokers or service providers. In certain cases, we may receive compensation if you choose to engage with these providers through our website. This helps support the ongoing operation of the site and allows us to continue publishing content at no direct cost to our readers. Our content is created with the aim of being informative and useful. While commercial relationships may exist, we strive to ensure that the information presented remains objective and based on our own research and perspective.
cross